American Academy of Dermatology, March 7 to 11
AAD: Baricitinib Efficacious for Hair Regrowth in Teens With Severe Alopecia Areata
Significantly more patients receiving baricitinib 2 mg, 4 mg had SALT score ≤20, ≤10 versus placebo at week 36
Roflumilast Cream 0.05 Percent Safe, Effective in Young Children With Eczema
Significant improvement in pruritus seen within 24 hours of first application
AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof
Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after treatment-free interval
AAD: Ivarmacitinib 4 mg, 8 mg Efficacious for Adults With Severe Alopecia Areata
No new safety signals or reports of deaths, thromboembolic events, or major cardiovascular events reported
Small Number of Acne Products Recalled for Problematic Levels of Benzene
Agency says 90 percent of tested products have undetectable or extremely low levels of benzene
Remibrutinib Beneficial for Urticaria After H1-Antihistamine Treatment
Remibrutinib results in significant improvement in composite measure of itching and hives at week 12 after second-generation H1-antihistamine treatment
Risk for Lymphoma, Skin Cancer Increased in Individuals With Tattoos
Increased risks seen based on twin cohort and case-cotwin studies
At-Home Light-Emitting Diode Devices Safe, Effective for Acne Treatment
Review finds red, blue, and combination wavelength devices are all effective
Overactive Bladder Positively Associated With Arthritis
Positive association seen between osteoarthritis and OAB, but not for rheumatoid arthritis or psoriatic arthritis
